Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LOC101927499 (ENSG00000298486, novel transcript, antisense to KIAA1644) is annotated as a long non-coding RNA gene, classified as a natural antisense transcript (NAT) overlapping the KIAA1644 locus in antisense orientation[2]. NATs are a broad class of endogenous RNA molecules with sequences complementary to other transcripts and are known, in general, to play roles in gene expression regulation, epigenetic modification, and chromatin remodeling[12][6]. However, there is currently no direct experimental evidence for the functional role, biological pathway involvement, or disease association specifically for LOC101927499[2]. It is not a known protein-coding gene, therapeutic target, receptor, enzyme, transporter, or clinically actionable locus. Its classification and annotation may be based on transcriptomics data without functional characterization[2]. This target does not meet typical criteria for a drug discovery or therapeutic target database entry, and there is no evidence of its involvement in pathophysiology or as a drug-interacting molecule.
null
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to KIAA1644 (null).